Sarcoidosis Animal Model Using M. Abscessus Cell Wall Microparticles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The lack of an appropriate animal model that accurately mimics sarcoidosis, particularly in terms of reproducibility and the manifestation of clinical symptoms such as pulmonary fibrosis and lymphadenopathy, limits understanding of the etiology and pathogenesis of sarcoidosis, hindering the development of effective treatments.
Innovation Solution
The development of animal models using Mycobacterium abscessus cell wall microparticles, which are administered to animals to induce granulomas that resemble sarcoidosis, including symptoms like pulmonary fibrosis and lymphadenopathy, by intratracheal or intranasal delivery, allowing for the study of disease mechanisms and potential therapeutic interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional animal models are used for sarcoidosis research, then the research process can proceed, but the models fail to accurately mimic clinical symptoms such as pulmonary fibrosis and lymphadenopathy, reducing reliability
Solution Approach 1:
The patent changes the key parameter of the animal model by using Mycobacterium abscessus cell wall microparticles instead of traditional models. This parameter change enables the model to accurately reproduce sarcoidosis clinical features including pulmonary fibrosis and lymphadenopathy, thereby improving both reliability and adaptability of the disease model
Solution Approach 2:
The patent creates an animal model that copies the key pathological features of human sarcoidosis. By administering M. abscessus microparticles, the model reproduces granuloma formation, pulmonary fibrosis, and lymphadenopathy that mirror human disease presentation, enhancing the model's ability to mimic clinical symptoms
2Reliability
If Mycobacterium abscessus cell wall microparticles are administered to induce granulomas, then the accuracy of sarcoidosis representation is improved, but the complexity of the method increases
Solution Approach 1:
The patent extracts the essential pathogenic element (cell wall microparticles) from the complete Mycobacterium abscessus organism. By using only the cell wall microparticles rather than whole bacteria, the method simplifies the administration process while maintaining the ability to induce sarcoidosis-like granulomas, thus improving reliability without excessive complexity increase
Solution Approach 2:
The cell wall microparticles serve as an intermediary that mediates the induction of granulomas without requiring live bacteria. This intermediary approach allows the model to reproduce disease features while avoiding the complexities and ethical concerns associated with live pathogen administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These models provide a more reliable representation of sarcoidosis, enabling better understanding of the disease and facilitating the development of targeted treatments by mimicking key clinical features and immune responses associated with sarcoidosis.
Implementation Method 1
The development of animal models using Mycobacterium abscessus cell wall microparticles, which are administered to animals to induce granulomas that resemble sarcoidosis
Implementation Method 2
contacting the second pellet with a lysis buffer and heating to a temperature of at least 90° C., wherein the lysis buffer comprises a protease inhibitor and a detergent; thereby forming Mycobacterium abscessus cell wall microparticles
Implementation Method 3
centrifuging the cells from (a) so as to produce a pellet and a supernatant liquid; and collecting the supernatant; (c) centrifuging the supernatant so as to produce a second pellet and a second supernatant liquid
Data Source
AI summary
The disclosure relates to a sarcoidosis animal model and methods of inducing sarcoidosis in an animal. The disclosure also relates to methods of producing an in vitro granuloma, and methods of using the sarcoidosis animal model. Disclosed herein are animals comprising one or more granulomas, wherein the one or more granulomas comprise Mycobacterium abscessus cell wall microparticles.